IBOGF: AI 评分 47/100 — AI 分析 (4月 2026)

Universal Ibogaine Inc. is a life sciences company focused on developing and operating addiction treatment clinics in Canada. The company is also pursuing clinical trials for ibogaine-based addiction therapy.

Key Facts: AI Score: 47/100 Sector: Healthcare

公司概况

概要：

Universal Ibogaine Inc. is a Canadian life sciences company specializing in addiction treatment clinics and the clinical research of ibogaine as a therapeutic for addiction. With a focus on addressing the opioid crisis, the company operates within the biotechnology sector, seeking innovative solutions for addiction management.

IBOGF是做什么的？

Universal Ibogaine Inc. is a life sciences company dedicated to developing and operating addiction treatment clinics across Canada. Founded with the mission to combat the growing addiction crisis, particularly the opioid epidemic, the company is exploring innovative treatment methods centered around ibogaine, a naturally occurring psychoactive substance. Ibogaine has shown promise in interrupting addictive behaviors and reducing withdrawal symptoms. The company's core business involves establishing and managing specialized addiction treatment centers that provide a holistic approach to recovery. These clinics offer a range of services, including medical supervision, psychological counseling, and aftercare support. Universal Ibogaine aims to create a safe and supportive environment for individuals seeking to overcome addiction. In addition to its clinic operations, Universal Ibogaine is actively engaged in clinical research to investigate the efficacy and safety of ibogaine-based therapies for addiction treatment. The company is planning clinical trials to gather scientific evidence and potentially pave the way for regulatory approval of ibogaine as a recognized treatment option. The company is headquartered in Calgary, Canada.

IBOGF的投资论点是什么？

Universal Ibogaine Inc. presents a speculative investment opportunity within the biotechnology sector, driven by its focus on ibogaine-based addiction treatment. The company's planned clinical trials represent a key catalyst, with positive results potentially leading to increased investor interest and future revenue streams. However, the company's negative P/E ratio of -4.16 and negative profit margin of -34.6% indicate financial challenges. The high beta of 4.61 suggests significant volatility. Success hinges on navigating regulatory hurdles, securing funding for research and operations, and demonstrating the efficacy and safety of ibogaine treatment. The stock currently offers no dividend yield.

IBOGF在哪个行业运营？

Universal Ibogaine operates within the biotechnology sector, specifically targeting the addiction treatment market. The demand for effective addiction therapies is growing due to the ongoing opioid crisis and increasing rates of substance abuse. The competitive landscape includes pharmaceutical companies developing traditional addiction medications and other biotechnology firms exploring alternative treatments. Universal Ibogaine's focus on ibogaine-based therapy differentiates it from competitors, but also introduces regulatory and acceptance challenges. The global addiction treatment market is projected to reach billions of dollars, presenting a significant opportunity for companies with innovative solutions.

Biotechnology

Healthcare

IBOGF有哪些增长机遇？

Expansion of Clinic Network: Universal Ibogaine can expand its network of addiction treatment clinics across Canada and potentially into other countries. The increasing demand for addiction treatment services, driven by the opioid crisis, creates a favorable environment for growth. Establishing new clinics in underserved areas can increase patient access and revenue. The timeline for expansion depends on securing funding and obtaining necessary regulatory approvals. The market size for addiction treatment services is estimated to be billions of dollars annually.
Clinical Trial Success and Regulatory Approval: The successful completion of clinical trials for ibogaine-based therapy could lead to regulatory approval by health authorities. This would allow Universal Ibogaine to market its treatment as a recognized and evidence-based solution for addiction. Regulatory approval would significantly enhance the company's credibility and market position. The timeline for regulatory approval depends on the progress of clinical trials and the review process of regulatory agencies. The market for approved addiction treatment medications is substantial.
Partnerships with Healthcare Providers: Collaborating with hospitals, rehabilitation centers, and other healthcare providers can expand Universal Ibogaine's reach and referral network. Forming strategic partnerships can increase patient referrals and integrate ibogaine therapy into mainstream healthcare settings. These partnerships can also provide access to additional resources and expertise. The timeline for establishing partnerships depends on negotiations and agreements with potential partners. The market for healthcare partnerships is significant.
Development of New Ibogaine-Based Therapies: Universal Ibogaine can invest in research and development to create new ibogaine-based therapies for different types of addiction and mental health disorders. Expanding the therapeutic applications of ibogaine can broaden the company's target market and revenue potential. This requires ongoing research and clinical trials. The timeline for developing new therapies depends on the complexity of the research and regulatory requirements. The market for new therapies is substantial.
International Expansion: Universal Ibogaine can expand its operations beyond Canada and establish treatment clinics in other countries with high rates of addiction. Entering new markets can significantly increase the company's revenue and global presence. This requires careful planning, market research, and regulatory compliance. The timeline for international expansion depends on the specific target markets and regulatory environments. The global market for addiction treatment is vast.

Market Cap of $0.00B indicates a micro-cap company with limited resources and higher risk.
P/E Ratio of -4.16 reflects negative earnings, suggesting the company is not currently profitable.
Profit Margin of -34.6% highlights significant operational inefficiencies and cost management challenges.
Gross Margin of 9.0% indicates a limited ability to generate profit from sales after accounting for the cost of goods sold.
Beta of 4.61 suggests the stock is significantly more volatile than the market average, indicating higher risk.

IBOGF提供哪些产品和服务？

Develops addiction treatment clinics in Canada.
Acquires existing addiction treatment clinics.
Operates addiction treatment clinics.
Conducts clinical trials for ibogaine-based addiction treatment.
Researches the use of ibogaine for addiction therapy.
Provides a holistic approach to addiction recovery.

IBOGF如何赚钱？

Generates revenue from operating addiction treatment clinics.
Provides medical supervision and psychological counseling services.
Conducts clinical trials and seeks regulatory approval for ibogaine-based therapies.

Individuals seeking treatment for addiction.
Patients struggling with opioid addiction.
Healthcare providers referring patients to addiction treatment clinics.

Focus on ibogaine-based therapy differentiates it from competitors.
Proprietary knowledge and expertise in ibogaine treatment.
Established network of addiction treatment clinics in Canada.

什么因素可能推动IBOGF股价上涨？

Upcoming: Planned clinical trials for ibogaine-based addiction treatment.
Ongoing: Expansion of addiction treatment clinic network in Canada.
Ongoing: Research and development of new ibogaine-based therapies.

IBOGF的主要风险是什么？

Potential: Regulatory hurdles for ibogaine treatment.
Potential: Competition from established addiction treatment providers.
Potential: Negative public perception of ibogaine.
Ongoing: Financial challenges due to negative P/E ratio and profit margin.
Ongoing: High stock volatility due to high beta.

IBOGF的核心优势是什么？

Focus on ibogaine-based therapy.
Planned clinical trials for addiction treatment.
Established presence in the Canadian addiction treatment market.

IBOGF的劣势是什么？

Negative P/E ratio and profit margin.
High beta indicates significant volatility.
Reliance on a single therapeutic compound (ibogaine).

IBOGF有哪些机遇？

Expansion of clinic network.
Regulatory approval of ibogaine-based therapy.
Partnerships with healthcare providers.

IBOGF面临哪些威胁？

Regulatory hurdles for ibogaine treatment.
Competition from established addiction treatment providers.
Negative public perception of ibogaine.

IBOGF的竞争对手是谁？

American Addiction Centers — Offers a wide range of addiction treatment services. — (AAGH)
Advaxis Inc. — Focuses on immunotherapy for cancer treatment. — (ADXS)
Agripharm Corp — Focuses on cannabis products. — (AGNPF)
Applied Biosciences Corp — Focuses on health and wellness products. — (APLIF)
Genpharm Inc. — Focuses on pharmaceutical products. — (GENPF)

Key Metrics

MoonshotScore: 47/100

Company Profile

CEO: Nicholas Peter Karos
Headquarters: Calgary, CA
Founded: 2022

AI Insight

AI analysis pending for IBOGF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Universal Ibogaine Inc. do?

Universal Ibogaine Inc. is a life sciences company focused on developing and operating addiction treatment clinics in Canada. The company is also engaged in clinical research to investigate the use of ibogaine, a naturally occurring psychoactive substance, for the treatment of addiction. Their business model centers around providing holistic addiction treatment services and advancing the scientific understanding of ibogaine's therapeutic potential. The company aims to address the growing addiction crisis by offering innovative and evidence-based treatment options.

What do analysts say about IBOGF stock?

As of 2026-03-17, there is no readily available analyst coverage or consensus on Universal Ibogaine Inc. (IBOGF) stock. The company's financial metrics, including a negative P/E ratio and profit margin, suggest it is currently not profitable. The high beta indicates significant volatility. Investors should conduct their own thorough research and consider the risks associated with investing in a micro-cap biotechnology company operating in a highly regulated industry. The stock's performance is closely tied to the success of its clinical trials and regulatory approvals.

What are the main risks for IBOGF?

Universal Ibogaine Inc. faces several key risks, including regulatory hurdles associated with ibogaine treatment, competition from established addiction treatment providers, and potential negative public perception of ibogaine. The company's financial challenges, as indicated by its negative P/E ratio and profit margin, also pose a risk to its long-term viability. Additionally, the high beta suggests significant stock volatility, which could lead to substantial losses for investors. The success of the company depends on the successful completion of its clinical trials and the acceptance of ibogaine as a legitimate treatment option.